Stockreport

Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH

Altimmune, Inc.  (ALT) 
NASDAQ:AMEX Investor Relations: altimmune.com/investors
PDF GAITHERSBURG, Md., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing therapies that address s [Read more]